» Articles » PMID: 35601881

Efficacy of Clofazimine and Nitazoxanide Combination in Treating Intestinal Cryptosporidiosis and Enhancing Intestinal Cellular Regeneration in Immunocompromised Mice

Overview
Date 2022 May 23
PMID 35601881
Authors
Affiliations
Soon will be listed here.
Abstract

is a widely distributed food and water-borne enteric protozoan that affects a wide range of vertebrates, resulting in life-threatening consequences, particularly in immunocompromised hosts. The lack of effective anti-cryptosporidial drugs may be related to the parasite's unique intestinal location, plus the lack of studies on the process by which the protozoan is able to impair intestinal cellular function. The present work aimed to assess the effect of clofazimine (CFZ), an FDA-approved drug for the treatment of leprosy, as an anti-cryptosporidial drug, using transmission electron microscopy (TEM) and an immunocompromised mouse model. The affected intestinal mucosa with parasitic stages in the infected non-treated group showed signs of severe cellular degeneration, including the loss of tight junctions, deformed and damaged microvilli and irregularly distributed nuclei with a severely vacuolated cytoplasm. Comparatively, nitazoxanide (NTZ) monotherapy showed the lowest efficacy as the drug was associated with the lowest rate of oocyst shedding. In addition, NTZ treatment failed to achieve the return of complete cellular function; abnormalities were evident in the microvilli, cytoplasmic organelles and nuclear features. Clofazimine demonstrated an improvement of the mucosal cellular components, including mitochondria and significantly reduced oocyst shedding. Combined treatment with low-dose CFZ and half-dose NTZ resulted in a significant improvement in the enterocyte cellular structures with an absence of intracellular parasitic stages. These results indicate that CFZ, a safe and readily prescribed drug, effectively reduces cryptosporidiosis when used in combination with only half the dose of NTZ. Used in combination, these drugs were shown to be efficient in regaining intestinal cellular activity following induced functional damage in an immunocompromised mouse model.

Citing Articles

Gut Barrier Dysfunction and Microbiota Variations in Cryptosporidiosis: A Comprehensive Review.

Ali M, Xu C, Wang M, Hina Q, Ji Y, Anwar S Vet Sci. 2025; 12(2).

PMID: 40005845 PMC: 11861801. DOI: 10.3390/vetsci12020085.


In vitro molecular assessment of parasitic load on human ileocecal adenocarcinoma cell culture after targeting by tavaborole (AN2690).

Mahgoub A, Gameil M, Abdelgawad M, Wanas H, Hamed A J Parasit Dis. 2025; 49(1):84-92.

PMID: 39975618 PMC: 11833033. DOI: 10.1007/s12639-024-01729-4.


Molecular pathogenesis of Cryptosporidium and advancements in therapeutic interventions.

Lu Y, Zhang X, Guan Z, Ji R, Peng F, Zhao C Parasite. 2025; 32:7.

PMID: 39902829 PMC: 11792522. DOI: 10.1051/parasite/2025001.


Houtt. methanol extract as a promising treatment for infection in experimentally immunosuppressed and immunocompetent mice.

El Shanawany E, Abouelmagd F, Taha N, Zalat R, Abdelrahman E, Abdel-Rahman E Vet World. 2024; 17(9):2062-2071.

PMID: 39507782 PMC: 11536736. DOI: 10.14202/vetworld.2024.2062-2071.


and evaluation of the anti-cryptosporidial activity of eugenol.

Gattan H, Wakid M, Qahwaji R, Altwaim S, Mahjoub H, Alfaifi M Front Vet Sci. 2024; 11:1374116.

PMID: 38515537 PMC: 10954888. DOI: 10.3389/fvets.2024.1374116.


References
1.
Xiao L, Bern C, Limor J, Sulaiman I, Roberts J, Checkley W . Identification of 5 types of Cryptosporidium parasites in children in Lima, Peru. J Infect Dis. 2001; 183(3):492-7. DOI: 10.1086/318090. View

2.
Rehg J, Hancock M, Woodmansee D . Characterization of a dexamethasone-treated rat model of cryptosporidial infection. J Infect Dis. 1988; 158(6):1406-7. DOI: 10.1093/infdis/158.6.1406. View

3.
Benamrouz S, Guyot K, Gazzola S, Mouray A, Chassat T, Delaire B . Cryptosporidium parvum infection in SCID mice infected with only one oocyst: qPCR assessment of parasite replication in tissues and development of digestive cancer. PLoS One. 2012; 7(12):e51232. PMC: 3521773. DOI: 10.1371/journal.pone.0051232. View

4.
Shini S, Aland R, Bryden W . Avian intestinal ultrastructure changes provide insight into the pathogenesis of enteric diseases and probiotic mode of action. Sci Rep. 2021; 11(1):167. PMC: 7794591. DOI: 10.1038/s41598-020-80714-2. View

5.
Khajah M, Luqmani Y . Involvement of Membrane Blebbing in Immunological Disorders and Cancer. Med Princ Pract. 2015; 25 Suppl 2:18-27. PMC: 5588526. DOI: 10.1159/000441848. View